



More clinical evidence for OXEPA®

Oxepa® works. Clinical trials show

- More ventilator-free days^{1,3,4}
- More ICU-free days^{1,4,5}
- Reduced new organ failures^{1,4}
- Reduced 28-day mortality rates⁴

Oxepa® – unique, specialized enteral nutrition therapy with

- EPA (eicosapentaenoic acid)
- GLA (gamma-linolenic acid)
- Elevated antioxidants

Oxepa® is clinically shown to modulate the inflammatory response in critically ill, mechanically ventilated patients.²


	ADULT					PEDIATRIC	
	Gadek ¹	Pacht ²	Singer ³	Pontes-Arruda ⁴	Elamin ⁵	Mayes ⁶	Nadkarni ⁷
Design	P,R,C,DB	P,R,C,DB	P,R,C	P,R,C,DB	P,R,C,DB	P,R,OL	P,R,C,DB
Setting	Multicentre 5 Sites U.S.	Single Center U.S.	Single Center Israel	Single Center Brazil	Multicentre 2 Sites U.S.	Single Center U.S.	Multicentre 5 Sites U.S.
Patients	146 ARDS	67 ARDS/ALI	100 ALI	165 Sepsis/ Septic Shock	16 ARDS	11 Burn & Resp Failure	26 ARDS/ALI
Interventions	Oxepa® vs Pulmocare®	Oxepa® vs Pulmocare®	Oxepa® vs Pulmocare®	Oxepa® vs Pulmocare®	Oxepa® vs STD	Oxepa®	Oxepa® vs PediaSure® 1.5
Outcomes							
Safety	●	●	●			●	●
Improved Oxygenation	●	●	●	●	●	●	
Reduced Time on Vent	●		●	●			
Reduced ICU LOS	●			●	●		
Reduced New Organ Failure	●			●	●		
Reduced Mortality				●			
Reduced Biomarkers of Inflammation		●					

KEY
 P = Prospective
 R = Randomized
 C = Controlled
 DB = Double-Blinded
 ICU = Intensive Care Unit

OL = Open Label
 STD = Standard Formula
 ARDS = Acute Respiratory Distress Syndrome
 ALI = Acute Lung Injury
 LOS = Length of Stay

NOTE:
 All ● are statistically significant ($p < 0.05$)

28-Day Period: ICU-Free Days



Pontes-Arruda A et al: *Crit Care Med* 2006;34(9):2325-33⁴



OXEPA[®]

Scientifically formulated...
 Clinically proven...¹⁻⁷
 Cost effective.^{8,9}

In light of the clinical evidence, can you afford not to use Oxepa[®]?

Cost of Care

Average Cost per Day	
ICU Bed	\$3,745 ⁸
Oxepa [®]	\$25 ⁹

Use under medical supervision

References: 1. Gadek JE, DeMichele SJ, Karlstad MD, et al. (Enteral Nutrition in ARDS Study Group): Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. *Crit Care Med* 1999;27(8):1409-20. 2. Pacht ER, DeMichele SJ, Nelson JL, et al. Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. *Crit Care Med* 2003;31(2):491-500. 3. Singer P, Theilla M, Fisher H, et al. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. *Crit Care Med* 2006;34(4). 4. Pontes-Arruda A, Arago AM, Albuquerque JD et al. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. *Crit Care Med* 2006; Vol. 34, No. 9. 5. Elamin ME, Hughes LF, et al. Effect of enteral nutrition with eicosapentaenoic acid (EPA), Gamma-Linolenic Acid (GLA), and Antioxidants Reduces Alveolar Inflammatory Mediators and Protein Influx in Patients with Acute Respiratory Distress Syndrome (ARDS). *Chest* 2005;128:225S. 6. Mayes T, et al. An evaluation of the safety and efficacy of an anti-inflammatory, pulmonary enteral formula in the treatment of pediatric burn patients with respiratory failure. *Nutr Clin Practice* 2005; Vol. 20, No. 1. 7. Nadkarni V, et al. *Crit Care Med* 2005; 33(Suppl 12):172M. 8. Academic Health Science Centre total per diem costs, Ontario Case Costing Initiative 2004/2005, Ontario Ministry of Health. 9. In the Gadek study (see reference 1 above), patients on average received 1728 Cal/day or 1152 mL/day or 48 mL/hr. Assuming a cost of Oxepa of \$124.52 per case of 24 (237 mL) cans, the cost of Oxepa is \$25 per day [1142 mL/day / 5688 mL/case x \$124.52 = \$25.00].